Form 8-A12B Acurx Pharmaceuticals,
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
ACURX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|(State of incorporation or organization)||(I.R.S. Employer Identification No.)|
|259 Liberty Avenue|
|Staten Island, New York||10305|
|(Address of Principal Executive Offices)||(Zip Code)|
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which
|Common Stock, $0.001 par value per share||The Nasdaq Stock Market LLC|
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box: x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box: ¨
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box: ¨
Securities Act registration statement file number to which this form relates: 333-256516
Securities to be registered pursuant to Section 12(g) of the Act: None
Item 1. Description of Registrant’s Securities to be Registered.
This registration statement relates to the registration with the Securities and Exchange Commission of shares of Common Stock, par value $0.001 per share (the “Common Stock”), of Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”). The description of the Common Stock set forth under the caption “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-256516) originally filed with the Securities and Exchange Commission on May 27, 2021 and as subsequently amended on June 11, 2021, together with the description set forth under such caption included in the form of prospectus subsequently filed by the Registrant with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, is incorporated herein by this reference in response to this item.
Item 2. Exhibits.
Pursuant to the Instructions
as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered
on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities
Exchange Act of 1934, as amended.
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
|Dated: June 23, 2021||ACURX PHARMACEUTICALS, INC.|
|By:||/s/ David P. Luci|
|Name:||David P. Luci|
|Title:||President and Chief Executive Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DIVIDEND 15 SPLIT CORP. Financial Results to May 31, 2021
- DIVIDEND 15 SPLIT CORP. II Financial Results to May 31, 2021
- Dorchester Minerals, L.P. Announces Its Second Quarter Distribution
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!